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I would like to analyze here advantages and disadvantages
of Japanese medical care for musculoskeletal tumors in my
experience, and to describe what we should do in the future
in order to enhance the advantages and overcome the
disadvantages.
I graduated from university and started my career as an
orthopedist in 1977. Also in that year, the Cancer Institute
Hospital of JFCR opened the Department of Orthopedic
Oncology, and clinical trials of high-dose methotrexate
(MTX) therapy commenced in Japan. In 1980, I started
working at the Cancer Institute Hospital and have been
heavily involved in medical care for bone and soft tissue
tumors since then. The following year, 1981, the hospital’s
original total knee replacement was first performed for
osteosarcoma, showing favorable response to neoadjuvant
chemotherapy.
Current medical care system
Tumors that orthopedists often deal with can include the
following three diseases: (1) metastatic bone tumors, (2)
benign tumors, and (3) sarcoma. While all these diseases
develop in the musculoskeletal system, different thera-
peutic strategies and systems are required to provide proper
treatment. In Japan, the three diseases are currently treated
in various medical facilities in an uncoordinated manner.
As for metastatic bone tumors, nowadays, it is said that
approximately 50 % of all people experience cancer during
their lifetime. The five most frequent cancers in Japan are
lung cancer, gastric cancer, colon cancer, breast cancer,
and liver cancer. For the purpose of providing equal
treatment for patients with the five major cancers anywhere
in Japan, the first basic measures against cancer were for-
mulated. As a result, 397 designated cancer hospitals had
been established by 2012. When surgery is required for
pathological fracture or spinal cord paralysis caused by
metastasis of the frequently seen cancers to bones, ortho-
pedists at the designated cancer hospitals provide the req-
uisite medical care.
The most important part of treatment for benign tumors
is to completely exclude the possibility of malignant
tumors. If there is even the slightest possibility of malig-
nant tumor in the image, a histological diagnosis is nec-
essary. If sufficient specimens can be obtained by needle
biopsy, the histological diagnosis can essentially be made
at any facility. On the other hand, if a diagnosis is not or
cannot be made by needle biopsy, further histological
examination, including incisional biopsy, is mandated.
With regard to treatment for a tumor confirmed as benign,
there is the option of follow-up. However, if the tumor has
already limited the activities of daily living or might limit
these activities in the future, surgery is deemed necessary.
For instance, even a benign bone tumor requires surgical
treatment if there is a risk of pathological fracture. Con-
sidering that pathological diagnosis, particularly by frozen
section, of bone and soft tissue tumors is difficult, and that
benign tumors may have a high rate of local recurrence,
even a benign tumor should be treated in a facility with
qualified orthopedists and pathologists specializing in bone
and soft tissue tumors.
The incidence of sarcoma is said to be just 1 % of all
malignant tumors, and as such is fortunately one of the rare
cancers. However, since sarcoma can develop in any part
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of the body, sarcoma of the bone, some parts of the ret-
roperitoneum and extremities, which are included in the
area of orthopedic care, account for almost 70 % of all
sarcomas. Unfortunately, we cannot state that the treatment
of sarcomas in Japan has been systematically carried out in
the past. It’s actually the reverse. Surgery is variously
performed by a mix of orthopedists, gastrointestinal sur-
geons, urologists, head and neck surgeons, gynecologists,
etc., depending on the site of occurrence of the sarcoma. In
terms of chemotherapy care, children may be treated by
pediatricians, whereas adults are treated not only by on-
cologists but by surgeons in several different specialty
areas. The reason behind this is that, in Japan, sarcoma
cases are dealt with across various clinical and hospital
facilities and no progress has been made in the intensifi-
cation and uniform handling of these cases. If the number
of cases per facility is small, it is not possible to create an
environment in which oncologists specializing in sarcoma
can grow their practices.
In sarcoma treatment by orthopedists, the history of
chemotherapy for sarcoma started with the introduction of
high-dose MTX therapy for osteosarcoma in the late 1970s.
The effectiveness of chemotherapy for Ewing’s sarcoma
was reported at around the same time and the necessity for
anticancer therapy of primary malignant bone tumors was
determined. Since the 1990s, when new drugs such as
doxorubicin, cisplatinum, and ifosfamide were released,
the survival rate of osteosarcoma patients has almost
reached a plateau. With regard to soft tissue sarcomas, the
clinical significance of chemotherapy for round cell sar-
comas has been well established, while the significance of
adjuvant chemotherapy for non-round cell sarcoma
remains unclear. With this background, no new medication
effective in treating sarcomas has been recently released.
Instead, progress in bone and soft tissue tumor treatment
after 1990 has been seen particularly in local treatment.
This progress in local treatment is supported by the
determination of the extent of resection to prevent local
recurrence and reconstruction to maintain good function
after resection.
Evaluation method of surgical margin and safety
surgical margin
We have seen that what is most important in the resection
of tumors is the surgical margin required to prevent local
recurrence. ‘‘The evaluation of surgical margin’’ [1] is a
method we use to describe the relationship between the
tumor and surrounding tissue as seen in surgical specimens.
Based on analysis of surgical specimens at the Cancer
Institute Hospital, the evaluation method of surgical margin
for musculoskeletal sarcoma was approved by the Japanese
Orthopedic Association Musculoskeletal Tumor Commit-
tee in 1989, which provides a basis for determining safety
surgical margins. The evaluation method consists of a
macroscopic evaluation of surgical specimens, performed
by means of converting not only the actual thickness
(distance) of normal tissue removed with a tumor but also
tissues (barriers) such as fascia and periosteum, which have
resistance to tumor invasion, into ‘‘distance.’’ In respect to
fascia surrounding muscles, for example, thick fascia is
converted into a ‘‘distance’’ of 3 cm and thin fascia into a
‘‘distance’’ of 2 cm. The surgical margin of the entire
circumference of the tumor is evaluated based on this
method and the minimal surgical margin determines the
presence or absence of recurrence; therefore, the type of
surgical procedure is decided by the minimal surgical
margin. Researching the relationship between the evalua-
tion method of surgical margin and the subsequent recur-
rence thus reveals the optimal extent of tumor removal.
We define surgical margins with local control rates of
90 % or more, as safety surgical margins. Safety surgical
margins in soft tissue sarcoma vary widely depending on
whether or not the tumor shows invasive growth. In the
case of non-invasive sarcoma, a wide procedure of 2 cm
would be safe for high-grade and a wide procedure of 1 cm
would be safe for low-grade. Even for high-grade, a wide
procedure of 1 cm is acceptable if preoperative treatment is
effective. However, in the case of invasive sarcoma, the
tumor easily invades surrounding tissue that does not play a
role as a barrier, and images cannot show the leading edge
of the tumor invasion. Therefore, setting safety surgical
margins is difficult and may lead to either excessive or
insufficient resection. If we can determine whether or not
the tumor is invasive by gene-level analysis and clarify the
extent of tumor invasion with bio-imaging in the future, a
more reliable determination of safety surgical margins will
become possible.
Surgical procedure for soft tissue sarcoma
Currently in the US, surgical treatment combined with
radiotherapy is the standard treatment for deep, high-grade
tumors. However, application of radiotherapy should be
limited due to time, cost, and serious complications such as
secondary cancers. Thus, surgery based on the concept of
safety margins is an important advance. When findings of
preoperative images confirm that a safety surgical margin
can be obtained by surgery alone, radiotherapy can be
excluded. In addition, when the findings cannot determine
whether an adequate safety surgical margin can be obtained,
there is also an in situ preparation (ISP) method [2] that
permits intraoperative evaluation of the safety margin
without increased risk of neoplasm seeding. This method
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enables resection of the tumor and surrounding healthy
tissue while maintaining the major neurovascular supply.
For this, after separating the tumor mass from the surgical
field by the use of a sterile vinyl sheet, the neurovascular
bundle is detached from the tumor and the surgical margin
is evaluated. If the bundle is seen to be contaminated by the
tumor, it should be excised. However, if the bundle can be
isolated, additional procedures including alcohol soaking
are performed to preserve it. With the concept of safety
surgical margins and the ISP method, unnecessary resection
and radiotherapy can thus be avoided.
Reconstruction after bone and soft tissue tumor
resection
The development of various skin flaps for treatment of skin
defects and improvement in the quality of artificial vessels
have played a significant role in improving function after
malignant tumor resection. For bone defects, significant
progress in tumor prosthesis and bone transplantation has
been achieved. Improvements in the quality and form of
tumor prosthesis have reduced the loosening or breakage of
artificial joints. In addition, improvements have been made
in resolving problems with expandable prostheses, such as
leg length discrepancy. Allografts used alone or with
metallic materials (allograft-prosthetic composite) have
played a key role in the reconstruction of bone defects.
In Japan, allografts have been difficult to obtain and
autogenous bone grafts (using autoclaved bone, boiled
bone, etc.) have long been performed. Since the Cancer
Institute Hospital started using pasteurized autogenous
bone graft [3] in the 1980s, research on recycled autoge-
nous bone graft techniques has become popular in Japan.
However, there are problems with recycled autogenous
bone grafts that are still to be resolved. The problems
include that the complete death of tumor cells cannot be
confirmed, the histological analysis of surgical specimens
may be insufficient, and the techniques cannot be used for
osteolytic lesions. In Japan, various recycled bone graft
techniques are developing even now, but more efforts
should be made to establish an allograft bone bank first,
rather than spending time and money on developing recy-
cled bone graft techniques.
Improvement of medical care system
for musculoskeletal tumors
The surgical procedures for bone and soft tissue sarcoma
may be significantly changed in the future, as evidenced by
the fact that the introduction of new drugs, including
molecular target drugs, has totally changed surgical
treatment for frequently seen cancers including breast
cancer. Although it remains in the distant future that
extended surgery and reconstruction will not be necessary
at all, there is a high possibility that the requirement for
extensive surgery will be reduced in the near future.
Medication-based treatment for bone and soft tissue
sarcomas is not necessarily considered to require its own
special attention but instead should be regarded as part of
the larger field of chemotherapy for sarcomas in general.
It is essential to establish a system of medical care for
musculoskeletal tumors as a way to reduce medical costs
and provide efficient medical care. Medical facilities can
be categorized as general hospitals, designated cancer
hospitals, specialized hospitals for bone and soft tissue
tumors, and specialized hospitals for sarcomas (sarcoma
centers). The role of general hospitals is to keep an eye out
for tumors and refer patients to appropriate hospitals as
necessary. Designated cancer hospitals provide diagnosis
and treatment for metastatic bone tumors. In specialized
hospitals for bone and soft tissue tumors, pathologists and
clinicians experienced in bone and soft tissue tumors pro-
vide diagnosis and treatment. In specialized hospitals for
sarcomas, medical care for sarcomas not only in the mus-
culoskeletal system but also in the whole body is given
systematically. The staff members are engaged in diagnosis
and treatment for sarcomas as well as study and education.
Sarcoma center
If sarcoma, which can appear in any part of the body,
develops in a location that makes it hard to remove, it is
extremely difficult to improve the patient’s prognosis. New
chemotherapy treatment inhibiting the growth of sarcomas,
etc., is vital to treat unresectable sarcomas. In recent years,
new medications such as trabectedin, pazopanib, etc., have
finally been released in the field of sarcomas; however,
those medications may have adverse reactions different
from those of traditional anticancer drugs, therefore treat-
ment by specialists in chemotherapy is recommended.
Also, in the field of musculoskeletal tumors, since ortho-
pedists provide both surgery and chemotherapy in the tra-
ditional system, they will have difficulty in dealing with the
plethora of new medications being released one after
another. It is thus essential to establish a system in which
oncologists specializing in sarcomas are in charge of
medication-based treatment for sarcomas. This requires
concentrating sarcoma patients in several facilities across
Japan and providing treatment. To achieve this, sarcoma
centers need to be established with the role of providing
systematic treatment for sarcomas. As for surgically based
treatment, surgical departments with the most anatomical
knowledge should provide treatment depending on the site
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of occurrence, and form the team to perform surgery as
needed. In respect to medication, oncologists specializing
in sarcomas should provide the treatment. It is also
required that research and clinical departments cooperate
with each other to develop new diagnostic treatment
methods using a wealth of surgical findings and accurate
clinical data. Such centers should be set up in Japan as
early as possible.
Finally, our Cancer Institute Hospital annually holds the
forum of the Surgical Society for Musculoskeletal Sarco-
mas. Young orthopedists responsible for the next genera-
tion of medical care for bone and tissue tumors and
international specialists participate in the forum. I recall
very well the words of the renowned orthopedist, Professor
Franklin H. Sim of the Mayo Clinic who said, ‘‘I am for-
tunate because I do not have to prescribe anticancer
drugs.’’ Orthopedists in Japan should be dedicated to per-
forming surgery and analyzing postoperative function and
the prognosis of patients. In addition, medication treatment
should be provided by specialists. To achieve these con-
ditions for optimum medical practice, it is essential to
establish specialized centers for sarcoma treatment.
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